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 Abstract 
 Over the past 6 years, next generation sequencing (NGS) 
has been established as a valuable high-throughput method 
for research in molecular genetics and has successfully been 
employed in the identifi cation of rare and common genetic 
variations. All major NGS technology companies provid-
ing commercially available instruments (Roche 454, Illu-
mina, Life Technologies) have recently marketed bench top 
sequencing instruments with lower throughput and shorter 
run times, thereby broadening the applications of NGS and 
opening the technology to the potential use for clinical diag-
nostics. Although the high expectations regarding the discov-
ery of new diagnostic targets and an overall reduction of cost 
have been achieved, technological challenges in instrument 
handling, robustness of the chemistry and data analysis need 
to be overcome. To facilitate the implementation of NGS as 
a routine method in molecular diagnostics, consistent qual-
ity standards need to be developed. Here the authors give an 
overview of the current standards in protocols and workfl ows 
and discuss possible approaches to defi ne quality criteria for 
NGS in molecular genetic diagnostics. 
 Keywords:  bioinformatics;  genetic variation;  Illumina; 
 library preparation;  Life Technologies;  molecular genetics; 
 molecular genetic diagnostics;  next generation sequencing 
(NGS);  rare diseases;  Roche. 
 Zusammenfassung 
 In den vergangenen 6 Jahren hat sich  “ next generation 
sequencing ” (NGS) als wichtige Hochdurchsatz-Methode 
f ü r die molekulargenetische Forschung etabliert und 
wurde erfolgreich zur Identifi kation seltener und h ä ufi ger 
genetischer Varianten eingesetzt. Alle gr ö ß eren NGS-Tech-
nologieunternehmen, die bisher kommerziell erh ä ltliche 
Ger ä te zu Verf ü gung stellten (Roche 454, Illumina, Life 
Technologies), haben vor kurzem auch  “benchtop ” -Ger ä te 
mit geringerem Durchsatz und k ü rzeren Laufzeiten auf den 
Markt gebracht, wodurch die Anwendungsgebiete erweitert 
und der Technologie der m ö gliche Einsatz in der klinischen 
Diagnostik er ö ffnet wurde. W ä hrend die hohen Erwartungen 
hinsichtlich der Entdeckung neuer diagnostischer Ziel-
strukturen und einer Senkung der Kosten erreicht wurden, 
m ü ssen etliche technologische Herausforderungen hinsicht-
lich Bedienung der Ger ä te, Robustheit der Chemie und Hand-
habung der Datenanalyse noch gemeistert werden. Um die 
Einf ü hrung von NGS in die Routinediagnostik zu erleichtern, 
m ü ssen nachhaltige Qualit ä tsstandards entwickelt werden. Im 
Folgenden geben die Autoren einen  Ü berblick  ü ber die gegen-
w ä rtigen Standards in den Protokollen und Arbeitsabl ä ufen 
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und diskutieren m ö gliche Ans ä tze Qualit ä tskriterien f ü r NGS 
in der molekulargenetischen Diagnostik zu defi nieren. 
 Schl ü sselw ö rter:  Bioinformatik;  genetische Variation;  library 
Herstellung;  Illumina;  Life Technologies;  Molekulargenetik; 
 molekulargenetische Diagnostik;  next generation sequencing 
(NGS);  Roche;  seltene Erkrankungen. 
 Introduction 
 During the past 6 years, the fi eld of DNA sequencing has dra-
matically changed by the advent of next generation sequenc-
ing (NGS) methods, which rely  – in contrast to traditional 
Sanger sequencing  – on massively parallel sequencing of short 
DNA fragments  [1 – 3] . Reaching an unprecedented through-
put, the cost of DNA sequencing decreased by several orders 
of magnitude. These sequencing techniques offer unique 
opportunities for molecular diagnostics such as enabling the 
identifi cation of disease causing mutations in rare and com-
mon genetic disorders, cancer diagnosis or rapid pathogen 
screening of microbial communities. Routine employment of 
NGS in diagnostics is very promising, yet many challenges 
remain. Researchers are continuously challenged with new 
procedures for sample preparation and tremendous increases 
of data volume requiring new analytical tools for data man-
agement. To meet the high-quality requirements for routine 
application and patient care, quality standards for the appli-
cation of NGS for molecular genetic diagnostics need to be 
defi ned. 
 An NGS workfl ow typically consists of the following 
steps: (i) library preparation, i.e., the preparation of the 
sample for sequencing, which in particular includes DNA 
quality control and quantifi cation, shearing of the DNA to 
fragments of the desired length and quality assessment of the 
fi nal library. (ii) With the cost of whole genome sequenc-
ing still being prohibitive for most applications, the second 
step comprises the enrichment of specifi c target regions of 
interest. Multiple approaches based on either hybridization 
of oligonucleotide probes complementary to the target region 
or amplicon amplifi cation are available. (iii) The third step 
consists of the actual sequencing, whereby each instrument 
has its specifi c characteristics and caveats. (iv) The fourth 
step involves data analysis using bioinformatic techniques to 
extract information from the massive amounts of raw data. 
Alignment of the raw reads to a reference sequence, iden-
tifi cation of regions with insuffi cient coverage and variant 
calling fall in this domain. (v) The fi nal step then consists 
of the validation of the identifi ed variants using traditional 
techniques. 
 Because errors can occur at every single step and consist-
ent quality standards are still missing, the defi nition of such 
standards should signifi cantly reduce the risk of generating 
false data and incorrect data interpretation, thus accelerat-
ing the adoption and implementation of NGS techniques for 
molecular diagnostics. Here we discuss platforms, workfl ows 
and data analysis parameters for diagnostic applications and 
highlight areas where quality criteria need to be defi ned. 
 Library preparation 
 DNA quantifi cation 
 For diagnostic analyses in general, but particularly for NGS 
procedures, DNA samples of high-quality and purity are 
required. Hence, the isolation system for genomic DNA 
should always be the same to generate reproducible results. 
Ideally, the DNA is prepared in the test performing laboratory 
according to the accredited standard operating procedure. To 
determine the quantity of DNA in a sample, a photometric or 
fl uorometric measurement is performed. 
 DNA concentration can be photometrically measured at a 
wavelength of 260 nm (A 260 ), whereas proteins are quanti-
fi ed at 280 nm (A 280 ). The quotient of both values (A 260 /A 280 ) 
should be in the range of 1.8 and 2.0 to guarantee a high purity 
of DNA. Thus, values lower than 1.8 indicate a high amount 
of protein. Owing to the absorbance maximum of carbohy-
drates at 230 nm, high levels of sugar, salts or organic sol-
vents are detected by a ratio A 260 /A 230 over 2.0. DNA samples 
out of the optimal range (below 1.8 and above 2.0) should be 
purifi ed with specialized kits. 
 There are multiple benchtop fl uorometer systems avail-
able for the quantifi cation of DNA, RNA and protein. Two 
examples of such instruments are the Qubit 2.0 fl uorometer 
(Invitrogen, Carlsbad, CA, USA) and the QuantiFluor system 
(Promega, Madison, WI, USA). Both systems use intercalat-
ing dyes that specifi cally bind to double-stranded DNA. First, 
a type curve with a known template has to be generated to 
calculate the regression formula. The fl uorescence from each 
sample is detected and by the regression formula the amount 
of molecules per  µ L is calculated. The software calculates 
the necessary dilution to achieve the desired concentration. 
The fl uorometric measurement has the advantage that it spe-
cifi cally determines double-stranded DNA content, which is 
critical because most NGS libraries are prepared exclusively 
from double-stranded DNA. 
 A similar concentration and purity of all analyzed DNA 
samples within one performance is important to guarantee a 
uniform amount of reads per target (coverage) in the subse-
quent sequencing reaction. 
 DNA shearing 
 Shearing of input DNA to smaller fragments of desired length 
(typically 300 – 1000 bp) is a key step in the library prepara-
tion workfl ow. The distribution of fragment length should be 
as uniform as possible. There are several shearing techniques 
available. These techniques include shearing by nebulization, 
sonication and enzymatic reaction. The benefi ts and caveats 
as well as the preferred sequencing system for each technique 
are discussed in the following sections. 
 Sonication
Covaris isothermal sonication  Fragmentation of 
genomic DNA using the Covaris Adaptive Focused Acoustics 
(AFA) process is regarded as the gold standard. The Covaris 
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instruments (Covaris, Woburn, MA, USA) work by sending 
acoustic energy wave packets from a transducer that con-
verges and focuses to a small localized area (Table  1 ). At this 
focal point acoustic energy creates cavitation, thereby pro-
ducing breaks in double-stranded DNA. Specifi c sample pro-
cessing tubes (micro/miniTUBES with AFA fi ber) and several 
operating conditions control fragment length (100 bp–5 kb) 
and distribution. Maximizing the yield of DNA fragments in 
the desired size (defi ned by mean peak base pair size) depends 
on the adjustment of following treatment attributes:
•  The sample volume should be adjusted with Tris-EDTA 
(TE) buffer to 200  µ L for miniTUBES and 130  µ L for 
microTUBES, but with an improved protocol volume can 
be reduced up to 50  µ L without any effect on shearing pro-
fi les. However, with lower volumes an air space may form 
in the sample fl uid; thus, partitioning the sample which 
sometimes may result in a broad peak. 
•  As the DNA fragmenting process is rate limited, fragment 
size generation is affected by treatment duration, which 
usually varies from 15 to 900 s depending on the instru-
ment, and acoustic parameters (duty cycle/duty factor, 
intensity/peak incident power, cycles per burst). The DNA 
amount can vary from 100 ng to 10  µ g and minor adjust-
ments must be set up depending on the amount and type of 
starting material, concentration, and/or viscosity. 
•  The bath water is employed to couple acoustic energy to 
the sample vessel. Daily change of pure distilled or DI 
water, proper water levels, controlled temperature, and 
degassing are critical for reproducible results. In a non-
degassed water bath dissolved oxygen reduces cavitation 
and disperses energy, reducing shearing effi ciency. 
 The Covaris AFA process has several advantages over other 
fragmentation methods. First, DNA is sheared in closed inde-
pendent vessels reducing sample loss and/or cross-contamina-
tion. Second, random break of DNA eliminates the risk of G/C 
bias, common with enzymatic shearing. Third, the system is 
automatable for higher throughput, up to 96 samples per run. 
Fourth, improvements to the shearing protocol in combination 
with removal of small fragments in subsequent bead-based clean-
up steps eliminates the need to size select and extract samples 
from agarose gels, a critical bottleneck in the overall process. 
Figure  1 gives an overview over the Covaris AFA Instruments. 
 Bioruptor  The bioruptor (Diagenode, Denville, NJ, USA) 
bath type sonicator generates unfocused acoustic energy, 
which is dispersed throughout the water bath and absorbed 
as heat energy. Therefore, ice must be fed to the water bath, 
and samples allowed cooling down after short bursts of soni-
cation. Alternatively, a water cooling system which allows 
continuous cooling of the water bath can be connected to 
the sonicator device. For preparation of sequencing librar-
ies from human samples for subsequent target enrichment it 
is recommended to use 3 – 5  µ g of double-stranded genomic 
DNA as starting material. However, smaller amounts of 
approximately 1  µ g might also be suffi cient. Fragment size 
depends on the number of sonication cycles applied  [4, 5] . 
For example, to obtain fragments of human genomic DNA 
with an average size of 150 bp using the bioruptor sonicator, 
ultrasound should be applied during three cycles of 15 min 
each at low power. Recently, a new version of the bioruptor 
sonicator specifi cally designed for sequencing library prepa-
ration (bioruptor NGS) has been launched. Compared to pre-
vious versions, the bioruptor NGS can be operated in a faster 
and more user friendly manner. Although bath type sonica-
tion may result in reduced yield of DNA fragments compared 
to isothermal sonication, it is a feasible and rather economic 
approach for sequencing library preparation. 
 Nebulization  Nebulization is a simple and cost-effective 
procedure easy to establish in every laboratory. DNA frag-
mentation occurs inside a nebulizer, a small plastic device that 
uses compressed air to atomize liquids, which is connected 
to a nitrogen or argon air tank, or laboratory compressed air 
line using appropriate connectors and tubing. The use of a 
 Table 1  Overview of Covaris Adaptive Focused Acoustics instruments. 
Product M-series S-series E-series L-series
Key features Single sample Single sample Multisample Multisample
parallel processing
Automation compatibility N/A  – personal 
DNA shearing
Yes  – S220R Yes  – E220R Yes  – LE220R
Application DNA shearing DNA shearing DNA shearing High throughput DNA shearing
Other Other Other
Target peak 200 – 3000 bp 150 – 5000 bp 150 – 5000 bp 150 – 5000 bp
Sample volume 50 – 200  µ L 50  µ L–10 mL 50  µ L–10 mL 50  µ L–200  µ L/tube
Models M220 S220 ™ E220 ™ LE220 ™ 
S220X ™ E220X ™ LE220R ™ 






150 300 500 1500
bp
 Figure 1  Example of an amplicon DNA library on a bioanalyzer. 
 The 150-bp peak indicates primer dimer. 
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regulator that allows accurate control of the pressure from 
10 to 60 psi is recommended. Nebulization requires puri-
fi ed DNA (0.5 – 10  µ g) mixed in fragmentation buffer which 
consists of 80 % glycerol and Tris-HCl (pH 8). Nebulization 
should be performed in an appropriate laminar fl ow cabinet 
to prevent contamination of the aerosolized solution and the 
nebulizer device should be placed on ice during fragmenta-
tion. The size of the fragments obtained by nebulization is 
determined chiefl y by the speed at which the DNA solution 
passes through the atomizer, altering the pressure of the gas 
blowing through the nebulizer, the viscosity of the solution, 
and the temperature. Minor changes in these parameters will 
optimize the size and range of the DNA fragments. Although 
this is an easy and quick method, it has some disadvantages 
compared to other DNA shearing techniques. The resulting 
DNA fragments are usually distributed over a broad range of 
sizes (200 – 1000 bp) and size selection is necessary in fur-
ther steps of the library preparation procedure. In addition, 
purifi cation of DNA after nebulization is required and DNA 
recovery is not always optimal if using low amounts of DNA 
(1  µ g or less). 
 Enzymatic fragmentation  The Nextera DNA Sample 
Preparation Kits (Illumina, San Diego, CA, USA) provide a 
fast and easy workfl ow, enabling sequencing ready libraries 
to be generated in 90 min starting with 50 ng genomic DNA 
or polymerase chain reaction (PCR) amplicons. The Nextera 
chemistry simultaneously fragments and tags DNA in a sin-
gle step using a transposon-based proprietary technology. A 
simple PCR amplifi cation then appends sequencing adapters 
and sample indices to each fragment. This method generates 
typical median insert sizes of  ∼ 300 bp and is compatible only 
to Illumina sequencing platforms. Following the addition of 
two indices to each DNA fragment, up to 96 uniquely indexed 
samples can be pooled and sequenced together in a single lane 
on any Illumina sequencer  [6] . 
 Gel and capillary electrophoresis  Most NGS tech-
nologies require that the DNA fragment sizes in the input 
library fall within a certain size range (due to, e.g., limita-
tions imposed by the bridge amplifi cation or emulsion PCR 
processes). Therefore, correct size distribution of the library 
needs to be ascertained to ensure satisfactory sequencing 
results. Traditional agarose or polyacrylamide gel electropho-
resis can be used especially when one can expect fragments 
with defi ned sizes that produce sharp, easily detectable bands 
(e.g., amplicon-based resequencing). For DNA fragment 
libraries with a spectrum of DNA segment lengths, special-
ized instruments (e.g., Agilent 2100 Bioanalyzer and 2200 
TapeStation, Agilent, Santa Clara, CA, USA; Bio-Rad Expe-
rion, Bio-Rad, Hercules, CA, USA) provide higher sensitiv-
ity and better size resolution. These instruments are based on 
capillary electrophoresis and DNA detection by fl uorescent 
dyes, integrated in a compact cartridge or microfl uidics chip. 
They not only allow precise library size determination but 
also detection of small contaminants such as primer dimers. 
This is important because presence of primer dimers in a 
sequencing library may cause artifacts that severely affect the 
output of a sequencing run. 
 Quantifi cation  The accurate quantifi cation is an impor-
tant step during NGS library preparation. In the three sys-
tems (Roche 454, Roche, Basel, Switzerland; SOLiD and Ion 
Torrent PGM, both Life Technologies, Carlsbad, CA, USA) 
which use emulsion PCR (emPCR) for amplifi cation, it is 
important to apply the correct amount of library molecules to 
the beads. To avoid mixed reads, there should be one read per 
bead. For the Illumina platforms it is important to calculate 
the accurate molarity for the cost-benefi t ratio of the run. This 
means, on the one hand, if the fl ow cell is loaded to sparse, 
sequencing yield will decline. On the other hand, if the fl ow 
cell is loaded to dense, signal overlap between adjacent clus-
ters reduces overall run yield and quality. There are several 
different methods to quantitate the library including fl uoro-
metric assays and quantitative PCR (qPCR), which is widely 
considered the most accurate. 
 Fluorometric quantifi cation:  DNA libraries can be meas-
ured using standard fl uorometric methods as previously 
discussed. 
 qPCR:  Sequencing performance depends on the amount of 
DNA fragments with correctly ligated adaptors and the effi -
ciency of library amplifi cation. Both factors can be measured 
using real time qPCR. The advantage of this method is that 
only fragments with both adaptors will be amplifi ed. Frag-
ments in which the ligation of one or both adaptors failed are 
not quantifi ed, avoiding an overestimation of fragments. It is 
recommended that the standard library should have a compa-
rable GC-content to the quantifi ed library, because it has been 
shown that GC-content can infl uence amplifi cation effi ciency 
in qPCR. As a standard either a plasmid library or an already 
successfully amplifi ed library can be employed. 
Automation 
 NGS techniques allow not only the simultaneous sequencing 
of all known genes associated with a certain disease but also 
the simultaneous sequencing of tens of patient samples in one 
sequencing run. It is therefore of great relevance to guaran-
tee identifi cation of each sample in the downstream analysis 
process, to have greatest possible reproducibility and to avoid 
any type of cross-contamination [31]. 
 The bottleneck occurs with the sample preparation before 
sequencing. As previously discussed in detail, current library 
preparation methods include DNA purifi cation, multiple 
quality control steps, adaptor ligation and target enrich-
ment, involving several repetitive purifi cation and pipetting 
steps. Manual methods are not only time consuming but also 
error prone with considerable variability. By contrast, auto-
mated sample preparation enables a higher throughput and 
an increased reproducibility by improving pipetting accu-
racy and avoiding sample mix-ups. Examples for automated 
library preparation are the Agilent Bravo (Agilent) for high 
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throughput applications and the AB Library Builder ™ Sys-
tem (Life Technologies) for low-to-medium throughput. 
 Contamination 
 One of the key advantages of NGS technology is the clonal 
sequencing of the target DNA. A prerequisite of the clonal 
sequencing is the amplifi cation of single molecules, which 
renders the method potentially susceptible to the contamina-
tion with extrinsic DNA. Contaminants may be derived from 
laboratory surfaces or from pipetting devices. In particular, 
enriched DNA libraries from earlier experiments may give 
rise to contamination of subsequent sequencing runs. By 
using a PCR amplicon strategy for DNA library preparation, 
huge amounts of PCR products are generated in the fi rst PCR. 
Amplifi ed DNA fragments are diluted more than a 1000-fold 
before clonal amplifi cation occurs in the second PCR. If even 
minimal amounts of contaminants are available in the work-
ing area, they can function as a template for the clonal ampli-
fi cation and thus be detected by sequencing. 
 To avoid false positive sequencing results, similar prac-
tices and tools as in set-up of a nested PCR must be applied 
for NGS. At least three laboratory areas must be defi ned and 
physically separated: pre-PCR,  “ clean ” post-PCR and post-
PCR. The usage of fi ltered tips and different sets of pipettes 
is an undisputable requirement. DNA extraction and the fi rst 
PCR are performed in pre-PCR area. No PCR products are 
allowed in this part of the laboratory and the movement of 
samples, equipment and all types of materials from the post-
PCR area into the pre-PCR must be avoided. A clonal ampli-
fi cation, e.g., emulsion PCR is prepared in  “ clean ” post-PCR 
area. The traffi c into this area must be reduced to a minimum. 
If dilution of the DNA library is needed, it should be diluted 
prior to introducing it into  “ clean ” post-PCR area. For the 
preparation of clonal amplifi cation in the  “ clean ” post-PCR, 
we recommend the use of special working cabinets or laminar 
airfl ow hoods, which can regularly be decontaminated with 
UV light. 
 The experiences in our laboratory with NGS technology 
impressively underline the importance of very strict compli-
ance with high quality standards. In spite of careful sample 
handling a cross-contamination was observed in human leu-
cocyte antigen (HLA) typing with NGS technology. In the 
search for possible contaminants, we identifi ed the source of 
false positive sequences. The emPCR was obviously contami-
nated with PCR products from earlier experiments. To our sur-
prise, this experiment was done already 3 months before the 
contamination occurred. All runs in between have shown no 
contamination with additional PCR products. Further quality 
assurance measures were taken afterwards and resolved the 
problem with contamination in subsequent sequencing runs. 
 Enrichment 
 Even though the raw cost of sequencing dropped signifi cantly 
with NGS technologies, the cost of sequencing a complete 
human genome is still prohibitive for most applications. 
Particularly for clinical diagnostics, only disease relevant 
genes and regions of interest are to be sequenced. To select 
these regions, several different approaches, either ampli-
con-based or based on oligonucleotide hybridization, are 
commercially available. The individual systems are briefl y 
highlighted in the following sections. Main performance met-
rics and quality criteria for sequence enrichment are listed in 
Table  2 (based on  [7] ) .
 Amplicon based enrichment 
 Singleplex PCR  Enrichment with singleplex PCR uses 
amplicon specifi c primers fused a universal linker tail in a 
fi rst PCR. These target specifi c PCR products are pooled and 
then amplifi ed in a second PCR with primers, consisting of a 
linker tail, MID-tag (patient specifi c) and at the end a sequenc-
ing adaptor, thereby extending them with the sequences that 
are required to initiate sequencing and to distinguish reads 
from the different patients. Because regular distribution of the 
single fragment amplifi cation effi ciency is the key step for 
a uniform distribution of coverage and to maximize sample 
size in a single experiment, design and validation of primer 
sets should be optimized very carefully for best performance 
of the PCR amplifi cation. Table  3 summarizes a singleplex 
PCR enrichment protocol successfully used in our laboratory. 
 Enrichment with singleplex PCR is a fast and simple 
approach when small numbers of gene-specifi c amplicons 
need to be investigated and is best suited for long read 
sequencing platforms (e.g., Roche GS-FLX, GS Junior sys-
tem). Commercially available sample preparation approaches 
can increase throughput, but are less cost effi cient for smaller 
experiments. Singleplex PCR has the advantage over mul-
tiplex PCR that one can control and optimize amplifi cation 
effi ciency for each single amplicon; thus, diminishing cover-
age bias. However, for a large number of samples the num-
ber of amplifi cation reactions may increase dramatically and 
automation is mandatory. In addition, self-designed PCR 
assays have the advantage that the same set-up as for Sanger 
sequencing can be maintained, facilitating confi rmation of the 
detected mutations afterwards  [8, 9] . 
 Multiplicom  The MASTR ( M ultiplex  A mplifi cation of 
 S pecifi c  T argets for  R esequencing) technology from Multipli-
com (Multiplicom N.V., Niel, Belgium) offers a cost-effective 
DNA target amplifi cation, minimizing hands-on-time. A Mul-
tiplexer ™ algorithm is used for primer design enabling simul-
taneous PCR amplifi cation of multiple target sequences, up to 
70 amplicons (140 primer pairs), under standard conditions. 
A simple two-step PCR protocol, without the need of product 
normalization, allows fl exible incorporation of MIDs (molec-
ular barcodes) in each amplifi ed product to unambiguously 
link each read to the sample it originated from. Some key 
advantages of the MASTR workfl ow include the low amount 
of input DNA (only 20 – 50 ng) needed per multiplex PCR 
reaction and standard laboratory equipment (PCR machine 
and fragment analyzer) is the only requirement. Optional 
labeling PCR for fragment analysis check on Genescan is also 
included in the kit. The assay was fi rst designed for use with 
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 Table 2  General performance measure and suggested quality standards for next generation sequencing  [7] . 
Performance measure Suggested quality standards
Position and size of region of interest 
(ROI)
The ROI targeted for sequencing should be defi ned according to a reference database [e.g., using 
NCBI RefSeq or consensus coding sequence (CCDS) identifi ers]. This is of particular importance 
if several transcript variants of a gene are known.
Fraction of sequencing reads aligned 
to ROI (on-target percentage, capture 
effi ciency)
Using a set of control samples, a reference range for the percentage of sequence reads aligning 
to the ROI should be established. Capture effi ciency should be assessed for each clinical sample, 
because variation may point towards poor material quality or technical problems.
Average read depth across ROI 
(coverage)
Using a set of control samples, a reference range for the average read depth typically achieved 
over the entire ROI should be established. Average read depth should be assessed for each clinical 
sample. Variation of read depth may point to poor quality of starting material, technical problems 
with sequence enrichment or sequencing, or may be caused by genomic alterations such as 
amplifi cations or deletions.
Fraction of ROI covered at suffi cient 
depth and with suffi cient quality a 
(distribution of coverage, uniformity)
A set of control samples should be used to defi ne areas within the ROI that are prone to receive 
below average coverage or yield low quality reads.
The overall number of sequencing reads should be adjusted to ensure adequate coverage in such 
 “ diffi cult-to-target ” regions. If suffi cient coverage of certain areas within the ROI cannot be 
reliably achieved by sequence enrichment/NGS, alternative strategies need to be established for 
genotyping these regions.
Sequencing results for each sample should be assessed for areas with unexpectedly low coverage, 
which may point to genomic alterations such as deletions or rearrangements.
Diagnostic reports should state whether the entire ROI was suffi ciently a covered, or whether there 
were any gaps in coverage.
Sensitivity, specifi city, accuracy, 
assessment of allelic bias or dropout
Assessments of sensitivity and specifi city are central to the validation of every sequencing-based 
test. However, some specifi c considerations apply with regard to sequence enrichment, as it adds 
opportunity for bias. Sequence variations (both germline variants and somatic mutations) may 
affect probe or primer binding and reduce capture effi ciency. This can lead to reduced or absent 
representation of one allele (allelic bias or allelic dropout).
Sensitivity and specifi city of a sequence enrichment/NGS-based test should be established using 
sets of positive and negative control samples characterized by an established reference method. 
The positive control set should include mutations at any known mutational hotspots. If type or 
location of mutations within the ROI are heterogeneous, the positive control set should encompass 
a representative spectrum of known mutations. The test set should also include any sequence 
variants which are either relatively common or have special clinical importance.
For each clinical sample, known polymorphic sites (e.g., SNPs) within the ROI should be routinely 
evaluated for evidence of allelic bias.
 
a
 “ Suffi cient ” refers to the number and quality of sequencing reads required for confi dent detection of genetic variants. These parameters closely 
depend on the algorithms and criteria used for variant calling (see section on single nucleotide variant calling). 
the Roche GS-FLX and GS Junior sequencers, but an adapted 
protocol for  “ short read sequencing platforms ” is now also 
available. 
 Highly multiplexed, amplicon-based systems for tar-
get enrichment  Several approaches for target enrichment 
based on highly multiplexed, sequence-specifi c generation of 
amplicons have been developed. Commercially available sys-
tems include the Illumina TruSeq Custom Amplicon (TSCA) 
and Agilent Haloplex systems. These systems can be used to 
target up to several hundreds of kilobases of sequence, and 
thus stand in between conventional singleplex or multiplex 
PCR, and hybridization-based methods (in-solution or array-
based hybrid capture)  [10] . Primer or probe sequences for 
these assays are designed by the manufacturers based on the 
desired target sequences, and reaction conditions are stand-
ardized. Thus, these assays require less optimization on the 
side of the end user than conventional PCR-based approaches, 
but also offer less possibility for adjustments in the case of 
diffi cult-to-target regions. Other advantages in comparison 
to conventional PCR include the larger size of targetable 
sequence, and the lower amount of input DNA required due 
to the higher level of multiplexing. However, multiplexing 
may also lead to problems with uneven coverage, whereas a 
carefully optimized PCR setup may provide more balanced 
coverage over the entire target region  [10] . Advantages of 
highly multiplexed amplicon-based approaches over hybridi-
zation-based target enrichment include faster and less labori-
ous library preparation (no DNA shearing, adapter ligation, 
or overnight hybridization steps required), lower input DNA 
requirements, and higher capture effi ciency especially for 
small target regions. 
 The Illumina TSCA system is specifi cally designed for use 
with the Illumina MiSeq sequencing platform. It is based on 
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 Table 3  Example for a singleplex PCR protocol. 
1. Singleplex PCR Primary PCR using primers modifi ed at their 5 ′ end with a universal linker sequence. A hot-start PCR program, 
choosing adequate linker tail pairs, and adjusting primer concentration (0.2 – 1  µ M) without affecting amplifi cation 
effi ciency are crucial to avoid primer dimer formation. In addition, a proof-reading polymerase and a maximum of 25 
PCR cycles with a touch-down PCR cycling program are recommended.
2. Singleplex PCR 
evaluation
Agarose gel by electrophoresis.
3. Purifi cation and 
normalization




Pooling of all amplicons derived from one individual in a length-weighted equimolar ratio (3  µ L for 200bp–250bp 
products, 3.5  µ L for 251bp–300bp, 4  µ L for 301bp–350bp, 5.5  µ L for 351bp–400bp, 8  µ L for 401bp–500bp products, 
12  µ L for 500–600bp products) improves uniform distribution of coverage. Automation is recommended.
5. Concentration MinElute PCR purifi cation Kit (Qiagen, Venlo, Netherlands).
6. Secondary PCR Second PCR using patient specifi c MID-tagged primers with linker tail and sequencing adaptor. The total number 
of PCR cycles (primary and secondary PCR) should not exceed 40; thus, the number of secondary PCR cycles will 
depend on the fi rst PCR.
7. Purifi cation Magnetic bead PCR purifi cation system should be used.
8. Evaluation Agilent Bioanalyzer (or similar). Libraries showing primer dimers on the electropherogram might be subjected to a 
second bead purifi cation. Because longer amplicons amplify less effi ciency during emPCR, thus introducing coverage 
bias, secondary PCR should be repeated for amplicon pools showing irregular amplifi cation patterns (libraries with 
stronger representation of short amplicons vs. long amplicons).
9. Quantifi cation PicoGreen.
hybridization of two oligonucleotide probes to the same strand 
of unsheared genomic DNA, followed by an extension-ligation 
reaction and subsequent PCR. Currently, up to 384 amplicons 
covering up to 96 kb of cumulative target sequence can be 
amplifi ed in a single reaction tube from 250 ng of input DNA. 
 The Agilent Haloplex system was developed based on 
the principle of selector probes  [11] . Following digestion 
of genomic DNA with restriction enzymes, hybridization to 
probes that are complementary to both ends of individual 
restriction fragments leads to the formation of circular mol-
ecules. These circles are closed by ligation and selectively 
amplifi ed, using universal priming sequences included in the 
capture probes. The approach currently can be scaled to target 
1 – 500 kb of sequence from 250 ng of input DNA. 
Hybridization based enrichment 
 NimbleGen  The NimbleGen (Roche NimbleGen, Madi-
son, WI, USA) enrichment protocol is optimized for the 
Roche 454 System. In contrast to other suppliers such as Agi-
lent or Illumina, which use a web design studio, the design of 
the baits is performed directly by NimbleGen. This enrich-
ment method employs 55 – 105 mer DNA baits, which are 
designed overlapping to cover the target region  [12] . There 
are currently two different kits available which offer two dif-
ferent quantities of baits (385 K or 2.1 M), resulting in a tar-
get region up to 5 Mb or up to 50 Mb, respectively; 500 ng 
of genomic DNA is used as input. An on-target ratio of 66% 
of the reads should be achieved. Reads are defi ned as  “ on-
target ” if they share at least 1 bp true overlap with the targeted 
region during alignment. Not all reads are expected to map to 
the target region. Off-target reads can result from unspecifi c 
hybridization of the baits to different genomic locations. This 
is especially problematic, if the underlying genomic context 
shares great similarity with additional genomic regions (i.e., 
repeat stretches, pseudogenes or regulatory motifs). These 
regions may lower the target enrichment effi ciency and speci-
fi city. Coverage per gene is uniformly distributed (Figure  2 ). 
The amount of mappable reads varies with different align-
ment settings. More stringent mapping parameters result in 
more reads being sorted out during alignment. In an experi-
ment performed in our laboratories the NimbleGen assay 
achieved high specifi city (Table  4 ). 
 Agilent  The SureSelect Target Enrichment (Agilent) work-
fl ow is a solution-based system utilizing 120-mer biotinylated 
RNA baits to capture regions of interest. Starting from genomic 
DNA, a shearing step produces small fragments that are then 
coupled to specifi c adaptors and indexes or barcodes. The 
sample is then hybridized with biotinylated RNA baits that 
are further selected by using magnetic streptavidin beads. The 
company offers different enrichment kits for whole exome [50 
Mb, if desired also V4 including untranslated regions (UTR)]. 
The different versions are optimized with respect to underrep-
resented regions in previous versions plus additional balanc-
ing of baits. Several other kits such as the X chromosome or 
the coding kinome are available. A customized design is pos-
sible through access of the web interface  “ eArray ” . 
 GC-content bias  A general problem of hybridization based 
enrichment systems is the infl uence of target sequence GC-
content. Hybridization effi ciency declines with higher levels of 
GC-content  [12] . The fi rst coding exons of genes are generally 
known to be GC-rich  [13] . Therefore, coverage and capture 
rate of the fi rst coding exons are highly variable (Figure  3 ). 
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 Figure 2  Coverage distribution of an assay containing 40 genes. 
 Green bars indicate the maximum coverage, blue bars denote the mean coverage of the gene. 
 Table 4  Overview of an assay containing 40 genes enriched with 
NimbleGen. 
Reference Total mapped 
reads
Mapped reads in 
targeted region
Specifi city
chr1 62.553 48.286 0.772
chr2   2.417   1.212 0.501
chr3 17.479 10.596 0.606
chr4 25.053 19.888 0.794
chr6 14.865 11.389 0.766
chr7   6.173   4.607 0.746
chr10   7.871   4.441 0.564
chr11 20.404   9.856 0.483
chr12 28.736 16.102 0.560
chr14 14.29   8.503 0.595
chr15   6.813   3.988 0.585
chr17   9.138   3.243 0.355
chr18 14.972 10.869 0.726
chr19   1.993   1.521 0.763
chr20   3.592   2.511 0.699
chr21   4.415   1.164 0.264
 Quality assessment: instruments 
 Roche 454 sequencing 
 The Roche 454 technology uses a combination of pyrose-
quencing and emPCR. The capacity of the GS-FLX platform 
is around 350 – 700 Mb per 10 h run, enabling the sequencing 
of amplicons and larger gene panels. By contrast, the GS-FLX 
is not economical in sequencing whole exomes or complete 
genomes. Targets captured by the NimbleGen/Roche enrich-
ment system (on array or in solution) are compatible with 
both 454 FLX and the benchtop version, the 454 GS Junior. 
 During emPCR, the enriched DNA is clonally amplifi ed 
on specifi c beads which are then individually placed into mil-
lions of reaction wells on the GS-FLX picotiter plate (PTP), 
each containing sequencing enzymes. Successive fl ows with 
one of the four deoxynucleotide triphosphates (dNTPs) result 
in incorporation by synthesis and consecutive localized lumi-
nescence, which is recorded by an integrated CCD camera 
 [1] . Roche recommends an enrichment of the beads in the 
range of 5 % – 20 % to achieve a successful sequencing run; 
90 % of the Raw Wells should be KeyPass Wells. At least 50 % 
of the KeyPass Wells should be passed fi lter Wells. 
 A major advantage of the 454 technology is the compa-
rably long read length that may reach up to 450 bp (up to 
1000 bp with the recently released GS-FLX + system, respec-
tively). The long reads are ideal for de novo sequencing of 
small genomes  – an application that is primarily benefi cial for 
microbiology. Human genetic diagnostics may take advan-
tage of nucleotide haplotype information over a range of 
hundreds of base pairs which can eliminate the need of segre-
gation analysis for two recessive mutations. Moreover, long 
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reads facilitate alignment in  “ diffi cult ” regions with repetitive 
sequences. The main issue of this technology includes sys-
tematic errors in homopolymeric regions, for more detailed 
discussion see ref.  [14] and section on False positives. 
 SOLiD 
 SOLiD (Sequencing by Oligonucleotide Ligation and Detec-
tion) is an NGS technology developed by Life Technologies 
and has been commercially available since 2008. The current 
version, the SOLiD 5500, is capable of producing up to 180 
GB of sequence during a 10-day run. A library of DNA frag-
ments is prepared from the sample to be sequenced, which 
is then used to generate clonal bead populations. These frag-
ments are bound to magnetic beads such that only a single 
species of fragment is present at each bead. In a comparable 
manner to 454 sequencing, emPCR is employed to amplify the 
fragments. The resulting PCR products attached to the beads 
are then covalently bound to a glass slide. In the sequencing 
reaction, a set of fl uorescence labeled di-base probes com-
pete for ligation to the sequencing primer. Specifi city of the 
di-base probe is achieved by interrogating every fi rst and 
second base in each ligation reaction. Multiple cycles of liga-
tion, detection and cleavage are performed with the number 
of cycles determining the eventual read length. The color sys-
tem is redundant as four distinct colors are used to detect the 
16 different dinucleotide combinations. This leads to the term 
 “ color-space sequencing ” . 
 The manufacturer claims that, as every sequence position 
is read out twice, the SOLiD system produces very high qual-
ity data with a per-base accuracy of  > 99.94 % and a consensus 
accuracy of 99.999 % at 15 × coverage. However, head-to-
head comparisons with other NGS platforms failed to demon-
strate superior accuracy for the SOLiD technology  [15, 16] . 
One study evaluated the SOLiD, Illumina and 454 platforms 
for single nucleotide polymorphism (SNP) genotyping in 
human samples, using Sanger sequencing and microarrays as 
the reference. In this study, overall variant call accuracy actu-
ally was slightly lower with the SOLiD than with the Illumina 
platform. Of note, SOLiD seems to have higher sensitivity 
for variant detection in regions with low coverage. With the 
SOLiD system, similar to the Illumina platform, sequencing 
errors predominantly seem to occur towards the 3 ′ ends of 
reads  [3] . It is important to recognize that the evolution of 
sequencing instruments and chemistry is extremely rapid, 
and therefore these comparisons performed 3 years ago may 
not adequately refl ect contemporary system performance. 
Regarding the situation in early 2012, the read length of 
the SOLiD system is limited at 75 bp for single-end reads, 
whereas 150 bp or longer reads can be achieved with the Illu-
mina platform. The shorter read length of the SOLiD platform 
may represent a disadvantage for certain applications such as 
amplicon resequencing. One issue specifi c to the SOLiD plat-
form is that calling multiple adjacent SNPs is computation-
ally more challenging, due to the  “ color space ” representation 
of sequence data  [17] . 
 Illumina sequencing-by synthesis (SBS) 
 SBS technology, fi rst introduced in 2006 by Solexa, is now 
marketed by Illumina  [2] . Sequencing takes place on the solid 
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 Figure 3  Coverage in relation to GC-content (in  % ) of the coding fi rst exons of an assay containing 40 genes. 
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DNA molecules are initially generated by a PCR-like process 
called bridge amplifi cation. The cyclic sequencing process 
then involves strand elongation by incorporation of fl uores-
cently labeled nucleotides and optical imaging. Subsequent 
cleavage of the fl uorescent dye together with a  “ reversible 
terminator ” enables further strand elongation in the following 
cycle. Currently, the Genome Analyzer (GA) IIx and HiSeq 
series instruments are capable of producing up to 95 Gb and 
600 Gb, respectively, of sequence output per run. Whereas 
these instruments are primarily used for large-scale research 
projects including whole exome or whole genome sequenc-
ing, the MiSeq benchtop sequencer (introduced in 2011) is 
marketed for applications such as targeted resequencing of 
disease gene panels. 
 Several studies have investigated the technology-specifi c 
error profi le of SBS sequencing technology. Overall, these 
studies show that base substitution errors are more fre-
quent than insertion/deletion type errors, and that the error 
rate increases in later cycles  [14, 18, 19] . Errors may pref-
erentially occur in specifi c sequence contexts, and there-
fore errors may be strand specifi c (i.e., occur only in reads 
mapping to either the forward or the reverse strand of the 
genome). Although the Illumina sequencing chemistry has 
undergone improvements over time, knowledge of such 
technology-specifi c error profi les is important to identify 
false positive variant calls caused by sequencing artifacts. 
In addition, a recent study compared the MiSeq system with 
two other  “ benchtop ” sequencers (Roche 454 GS Junior and 
Life Technologies Ion Torrent PGM) and concluded that the 
MiSeq offered the lowest error rate of the three instruments, 
with a substitution error rate of 0.1 per 100 bases and  < 0.001 
indel errors per 100 bases for 2 × 150 bp paired-end reads 
 [14] . Of note, this study looked at de novo sequencing of 
a bacterial genome, and it is unclear if the same error rates 
apply to other applications such as targeted resequencing 
of human genes. A study evaluating the HiSeq and GAIIx 
platforms using plant and viral genomes showed comparable 
error rates, with substitution rates of 0.11 % – 0.16 % for the 
HiSeq and 0.28 % for the older GAIIx instrument, and indel 
rates of  < 3 × 10  – 5  [19] .  Illumina has stated some basic quality 
criteria for a successful MiSeq instrument run, these include, 
for a 2×150 bp run: 
•  Phred-scale quality scores of at least 30 for  > 75 % of all 
bases for a 2 × 150 bp run. 
•  Cluster densities of 50 – 1300 K/mm 2 , ideally 800 K/mm 2 . 
•  Fluorescent signal intensities of  > 200 units for all four 
bases throughout the run. 
•  Sequence yield  > 1 GB. 
 These criteria probably represent conservative estimates 
of instrument performance, and the results observed in 
practice will depend on the specifi c assay in use. Therefore, 
users should carefully monitor run parameters over time to 
detect suboptimal instrument runs, even if they fall within 
the above specifi cations. Additionally, we recommend 
inclusion of a control library containing a known sequence 
(e.g., the phiX viral genome) with every instrument run. 
This allows direct measuring of the sequencing error rate 




 A key point in the analysis of NGS data is sequence align-
ment, where millions of short reads have to be aligned to a 
reference sequence in a reasonable time. A variety of different 
alignment algorithms and strategies have been implemented 
since NGS has been available  [20] . Each alignment algorithm 
has certain advantages and disadvantages and is tailored to 
a specifi c instrument for which it was primarily designed. 
The choice which program performs best is left to individual 
user ' s preferences; however, two important aspects need to 
be considered. The differences and implications when using 
a local vs. a global alignment algorithm and the concept of 
mapping uniqueness, particularly how the chosen algorithm 
handles non-uniquely mapped reads. The handling of these 
reads can signifi cantly infl uence variant calling results. 
 Global alignment attempts to align the read over the full span 
of bases, whereas local alignment algorithms trim mismatching 
bases at the ends of reads. In turn, local alignments typically 
lead to a greater number of aligned reads and thus more pro-
duced data, but may also introduce certain mapping biases. By 
contrast, global alignments maximize alignment quality at the 
cost of a greater portion of reads that cannot be aligned. 
 Mapping uniqueness addresses the problem that a given 
read can have more than one match to the reference sequence. 
The multiple hits are a result of underlying sequence similar-
ity in the reference genome, for example, in repeat regions 
or pseudogenes. There are several ways to defi ne mapping 
uniqueness, one of the most widely adopted being the fol-
lowing. A read is uniquely mapped if its best hit contains less 
mismatches to the reference sequence than its second best hit. 
There are currently two alternatives in dealing with such reads: 
(i) discard all non-uniquely mapped reads or (ii) randomly 
choose a position to align each read but fl ag them as non-
unique. Flagged reads are then ignored during variant calling 
and thus do not contribute to variant calls. The second option 
has the advantage that even though the reads are non-uniquely 
mapped, they still can provide valuable information in overall 
coverage and repeat content of the sequenced region. 
 Single nucleotide variant calling 
 Per base coverage is an important criterion to assess the reli-
ability of a variant call at any given genomic position. For 
use in clinical, a minimum coverage should be defi ned, 
which is required to determine the underlying genotype with 
confi dence. Variants below the minimum coverage threshold 
need to be confi rmed by an independent technology. Although 
the coverage required for diagnostic applications depend on 
the employed sequencing platform, some general considera-
tions apply. 
 First of all, the read coverage of NGS runs is not uniformly 
distributed  [21] . Coverage for all instruments is reduced in 
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regions with an extreme AT- or GC-rich background. The 
coverage fl uctuation may require a higher  “ average ” coverage 
to assure that each base has the previously defi ned  “ minimal ” 
coverage for variant calling. For example, to reach a probabil-
ity of  > 99 % accuracy for each allele at a heterozygous posi-
tion at least twice, a coverage of 12-fold or more is needed 
[assuming probability (sequencing allele A) = probability 
(sequencing allele B) = 0.5; see supplementary Eq. (1) in the 
supplementary data  which accompanies this article at http://
www.degruyter.com/view/j/labm.2012.36.issue-4/issue-fi les/
labm.2012.36.issue-4.xml]. The presence of both alleles in at 
least two independent reads is considered the baseline crite-
rion for a heterozygous variant call. 
 In addition, coverage distribution of the two alleles in the 
case of a heterozygous position is typically biased towards 
the reference allele. Variant alleles are treated as mismatches 
to the reference sequence during the alignment step. There-
fore, these reads are more diffi cult to align on average. A 
portion of variant reads will be dropped during alignment, 
particularly if sequencing errors coincide with genuine vari-
ants in these reads. Further quality criteria for a reliable vari-
ant call include: (i) the average quality of the variant bases, 
(ii) indication of the variant alleles by reads from both the 
forward and the reverse strand, and (iii) the number of variant 
calls at the surrounding region. Although the defi nite num-
bers have to be individually adjusted to the specifi c applied 
NGS technology, we propose the following general thresh-
olds for NGS in a diagnostic set-up. (i) To achieve a sensitiv-
ity of more than 99 % variant detection, a coverage of 30-fold 
is required. (ii) The variant allele should be sequenced by at 
least two independent reads from either strand. In the case 
of a heterozygote variant, the ratio of variant reads/reference 
reads should be in the range of 0.1 – 0.9. (iii) Regarding qual-
ity values, we propose a minimum of Q30 average base qual-
ity at the variant position; however, it has to be considered 
that adjustments to the quality value threshold comprise a 
trade-off between sensitivity and specifi city. Higher qual-
ity values result in a lower false positive rate, whereas the 
false negative rate possibly increases as some genuine vari-
ants can be fi ltered out. (iv) In the case where three or more 
variants coincide in any window of 10 bp, all variants should 
be fi ltered out. Variants appearing this clustered are often an 
indication of problems such as pseudogenes or repeats in the 
underlying genomic context. An example of an identifi ed 
mutation in the  KRAS and some of the quality criteria dis-
cussed can be seen in Figure  4 . 
 Small insertion and deletion calling 
 The identifi cation of short insertions and deletion (Indels) are 
inherently more diffi cult to detect than single nucleotide vari-
ation. Because NGS alignment algorithms are built primar-
ily for speed to handle the massive amount of raw data, they 
tolerate only a certain number of mismatches to the reference 
sequence. The gaps introduced by Indels render the reads with 
this type of variation increasingly more diffi cult to align with 
a growing Indel length. The quality criteria above are gener-
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 Figure 4  Point mutation in the KRAS proto-oncogene identifi ed 
by exome sequencing of an acute promyelocytic leukemia sample 
(APL)  [22] . 
 (A) Exome data set of the leukemia sample is displayed using the 
integrative genomics viewer  [23] . Vertical gray bars represent the 
read depth at each position of the reference sequence. Horizontal gray 
bars symbolize the 76-bp reads aligned to the reference sequence. 
The frequency of 63 % of the mutant nucleotide A in the diagnostic 
leukemia sample indicates a heterozygous point mutation causing 
an amino acid substitution (G12V). (B) Capillary sequencing of the 
leukemia sample confi rmed the heterozygous mutation (upper panel), 
whereas absence of the mutation in the germline control sample from 
the same patient (lower panel) indicates somatic status. 
length exceeding  ∼ 20 nucleotides will be diffi cult to detect. 
Paired-end reads generated by the Illumina platforms can help 
to circumvent this problem. As two reads from the ends of the 
same DNA fragment are generated, initially unaligned reads 
are submitted to a second, more sensitive but slower align-
ment algorithm. This second round of alignment is not per-
formed on the whole genome, but the already aligned paired 
read is used as  “ anchor ” so that only the immediate vicinity 
of this read is used as reference (Supplementary Figure 1). 
 Detection of tumor-specifi c variants 
 For the systematic detection of tumor-specifi c sequence vari-
ants on a genome-, exome- or transcriptome-wide level, it 
is inevitable to compare tumor and germline control sam-
ples from the same individual  [22, 24 – 26] . Although these 
approaches are only about to enter the diagnostic routine and 
still require sophisticated fi ltering of variants, there are certain 
general considerations which need to be taken into account 
when dealing with variant detection in tumor samples. Any 
tumor sample is a mix of tumor and normal cells (e.g., stromal 
cells, infi ltrating white blood cells). Therefore, the threshold 
for calling a somatic variant needs to be adjusted to the per-
centage of tumor cells in the sample  [27] . Because any tumor 
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results from clonal expansion of a cell undergoing malig-
nant transformation, different subclones may arise. Whereas 
certain mutations are common to all tumor cells, others are 
uniquely associated with the evolution of subclones  [28, 29] . 
Hence, it is very challenging to defi ne a universal threshold 
for the allele frequency of a tumor-specifi c variant call, espe-
cially if the amount of tumor cells in the sample is not known 
or mutations in subclones of the tumor might have diagnos-
tic implications. In general, it might be useful to set a lower 
cut-off level for the allele frequency and a higher minimum 
coverage when looking for somatic variants in tumor samples 
in comparison to the detection of germline variants in non-
tumor samples. 
 False positives 
 Even though stringent quality criteria are applied during vari-
ant calling, some systematic errors of the different sequencing 
systems remain and must be considered. The most well-
known systematic error type is the problem of determining 
the exact length of a homopolymer stretch in 454 and Ion Tor-
rent sequencing. These systems use fl ow-based sequencing 
approaches which mean that multiple identical nucleotides 
are incorporated in a single fl ow. The emitted signal (fl uores-
cence signal in the case of 454 or pH shift in the case of Ion 
Torrent) is in theory proportional to the number of incorpo-
rated nucleotides. However, in practice signal strength does 
not increase linear with growing homopolymer length, result-
ing in exceeding diffi culty to call the correct number of bases 
with increasing homopolymer length  [1, 14, 30, 31] . 
 In addition to these error types, general error profi les are 
non-randomly distributed. In a given read sequencing errors 
tend to accumulate towards the read end. With growing 
read length fl uorescent signals may gradually decay making 
it increasingly diffi cult to determine the accurate nucleo-
tide. Furthermore, in the case of the Illumina cluster based 
sequencing phasing problems increase with growing read 
length. Dephasing is the term used to describe single mol-
ecules which either had a failed nucleotide incorporation in 
any sequencing cycle and are thus  “ lagging ” behind in their 
respective cluster or exhibited the incorporation of multi-
ple nucleotides in a single sequencing cycle (and are now 
 “ ahead ” in the cluster). These out-of-phase molecules will 
continue to emit a false signal in all following sequencing 
cycles  [2] . 
 In summary, knowledge of the individual strengths and 
weaknesses of the employed sequencing system have to be 
taken into account, when data are analyzed and interpreted. 
Moreover, a variant calling algorithm exploiting the specifi c 
error models of the instruments should be used. 
 Validation 
 Sanger sequencing 
 From our perspective, Sanger sequencing is currently still 
the gold standard for validating variants detected by NGS. 
Worldwide, there is more than 20 years of experience with 
this technology, although the sensitivity for the detection 
of minorities against a wild type background by the Sanger 
method is substantially lower compared to NGS (see also 
below). Because, even in a highly automated process, cross-
contaminations with another patient ' s DNA cannot be fully 
excluded, it currently remains important to confi rm all iden-
tifi ed pathogenic aberrations concerning the germline by 
Sanger sequencing. 
 There are two approaches to validate the results of NGS 
with Sanger sequencing. First, aberrations detected in a 
patient ' s sample by Sanger sequencing can be resequenced 
with an NGS method. Thus, identical results in both proce-
dures can serve to validate the data. The second approach 
to validate NGS data is resequencing of the entire region by 
Sanger and to match both data sets. Either way, we propose 
that a minimum of 10 independent samples should be com-
pletely analyzed in parallel for all diagnostically relevant 
genes to complete the validation process. The validation of 
large gene panels with up to 100 genes and more is very costly 
and labor intensive and may undergo at least a limited vali-
dation process by resequencing the detected variations. The 
limitations in the validation process should be documented in 
the  “ methods ” section in a medical report. 
 Regarding allele frequency, Sanger sequencing is limited 
in the detection of low frequency variants ( < 10 % variant fre-
quency). In the case of certain disorders, in particular cancer, 
where low frequency, tumor-specifi c variants are expected, 
different validation techniques need to be applied. A detec-
tion rate as low as  ∼ 5 % can be achieved using fi rst generation 
pyrosequencing, whereas using allele-specifi c PCR and real 
time PCR theoretically offers a detection rate of a single mol-
ecule in a background of 10 6 molecules. 
 Outlook 
 NGS has the potential to revolutionize genetic diagnostics. It 
allows the study of larger regions of the genome for disease 
causing mutations, an approach that would be too cost- and 
labor-intensive with traditional methods. By using NGS, the 
diagnostic spectrum will be expanded from Mendelian dis-
eases to polygenic disorders, which require the simultaneous 
study of several different loci. Currently, a multitude of differ-
ent platforms are available, yet only a few independent stud-
ies comparing different approaches have been carried out so 
far. With the increasing use of NGS in molecular diagnostics, 
consented quality criteria need to be further elaborated. These 
criteria will depend on the specifi c assay, the sequencing plat-
form and the clinical application. Still, considerable technical 
challenges remain to be mastered. For example, Indels and 
structural variations (large deletion/insertions, translocation) 
are diffi cult to detect. For the analysis of disorders, which 
frequently exhibit these types of mutations, other analytical 
approaches may be more suitable. It should also be mentioned 
that the cost benefi t can only be fully exploited if the enor-
mous capacities of the sequencing instruments are completely 
utilized. With the increasing size of gene panels studied by 
NGS, the time and manpower required for validation and 
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interpretation of variants needs to be considered. Neverthe-
less, we expect that further technical developments and stud-
ies address these issues and that NGS will continue to become 
an essential tool not only for research but also for molecular 
diagnostics. 
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